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Introduction of combination ART was instrumental to mitigate the burden 
of HIV pandemic in Ethiopia and other resource limited settings. 
Combination ART archives sustained HIV viral suppression and contributes 
to reductions in mortality, progression to AIDS, opportunistic infections 
(OIs), and hospitalization (1). Viral suppression is also associated with 
decreased HIV transmission to uninfected persons. In Ethiopia, improved 
coverage of free antiretroviral therapy (ART) program helped to enroll 
hundreds of thousands of ART needy people living with HIV; an overall 
ART coverage reached 73% (2-3).  
Failure of antiretroviral treatment and toxicity are feared complication of 
long-term ART users. Noncompliance to medical instruction and poor 
adherence fosters emergence of drug resistant mutant. An observational 
cohort study from HIV clinic in South Africa which enrolled 19,645 
patients (29,935 person-years) showed that 9.9% of first line ART (4.5/100 
person-years) failed at median 16 (IQR: 12–23) months following ART 
initiation. Five years following ART treatment, the failure rate was 16.9% 
and 7.8% when using a confirmatory threshold of 400 and 10,000 
copies/ml, respectively. The same study reported a 10.1% overall rate of 
switch to second-line by five years on ART (4). The emergence of primary 
and secondary HIV drug resistance is on the rise due to accumulation of 
mutant HIV strains and weak error proof reading capability of the virus. A 
systematic review of studies on prevalence of HIV-1 drug resistance in 
treatment-naïve individuals in resource-limited settings since roll out of 
ART programs, showed the highest estimated rate of increase at 29% per 
year (95% CI 15 to 45; p=0.0001) in East Africa; an estimated prevalence of 
HIV-1 drug resistance at eight years after ART program is 7.4% (5). 
Moreover, there is an increase incidence of resistance to non-nucleoside 
reverse transcriptase inhibitors in East Africa (36% per year; p<0·0001) and 
Southern Africa (23% per year; p=0·0049). Among the subset of studies 
reporting treatment failure with HIV-specific resistance mutation data (27 
studies with 734 patients), the most common mutations were the M184V 
mutation, found in 65% of patients, and the K103N mutation, found in 52% 
of patients (5-6).  
The clinical and epidemiological implications of drug toxicity and treatment 
failure from HIV drug resistance are huge. In addition to mortality and 
morbidity, the increased transmission of HIV resistant virus to intimate sex 
partners and increased health care cost will be enormous. At individual 
patient level, failed ART regimen or HIV drug resistance limits treatment 
options,complicates succession of therapy and puts the patient at increased 
risk for drug toxicity from second-line regiments who may need close 
vigilance and laboratory monitoring. In addition, limited availability 
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of laboratory services such as drug toxicity screening, 
HIV virology and drug resistance testing monitoring 
may contribute to delay in diagnosis of treatment 
failure in resource limited setting where virology 
monitoring is not a component of routine ART 
monitoring (6-8). 
The World Health Organization (WHO) recommends 
viral load determination, if feasible, to improve the 
identification of treatment failure. Due to financial and 
logistical constraints in resource limited settings, 
however, access to this expensive and technically 
demanding test is limited. Therefore, as a substitute, 
WHO-recommended clinical criteria and CD4 cell 
counts are commonly used by clinicians to diagnose 
ART failure and guide treatment switch (9). In the 
absence of viral load monitoring, unnecessary regimen 
switches are common, resulting in increased treatment 
costs and loss of future options for treatment 
succession. Also, late detection of treatment failure 
results in high frequencies of accumulated mutations 
conferring broad cross-resistance to NRTIs, which may 
impair the  
It is vital to understand factors that determine success 
of ART and treatment follow up for such evidence 
informs program monitoring, quality and safety of HIV 
prevention, treatment and care services in Ethiopia.  
In this special edition of the EJHS, the authors present 
readers insightful articles on antiretroviral therapy 
program in Ethiopia with emphasis on antiretroviral 
therapy monitoring and lessons learnt from the ACM 
cohort of HIV positive individuals enrolled to ART 
program in seven university hospitals at higher 
education institutions across Ethiopia.     
It is very much hoped that esteemed readers will read 
through the articles in this edition. It is also believed 
that the evidences and lessons learnt from these articles 
will encourage further research, incite scientific debate 
on treatment monitoring and inform national guidelines 
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